NK-One Therapeutics, Inc.
New Form D on file · 2026-04-27 · the record
What the record says
Trailing twelve months. 716 filings in Biotechnology, totalled by week. The dot is this raise, $290K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Company officers on record
On the filing as: Executive Officer, Director.
Michael Shine is named as Chief Executive Officer and President on the Form D that NK-One Therapeutics, Inc. filed with the SEC on 27 April 2026, one of 2 people that filing names.
On the filing as: Executive Officer, Director.
Marco Pappagallo is named as Secretary on the Form D that NK-One Therapeutics, Inc. filed with the SEC on 27 April 2026, one of 2 people that filing names.
2 people named on the filing — 2 holding an executive role.
Named as of the 2026-04-27 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on NK-One Therapeutics, Inc.
- Source Check — verify Michael Shine's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Michael Shine for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist NK-One Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind NK-One Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.